TY - JOUR T1 - Duration of viable virus shedding in SARS-CoV-2 omicron variant infection JF - medRxiv DO - 10.1101/2022.03.01.22271582 SP - 2022.03.01.22271582 AU - Julie Boucau AU - Caitlin Marino AU - James Regan AU - Rockib Uddin AU - Manish C. Choudhary AU - James P. Flynn AU - Geoffrey Chen AU - Ashley M. Stuckwisch AU - Josh Mathews AU - May Y. Liew AU - Arshdeep Singh AU - Taryn Lipiner AU - Autumn Kittilson AU - Meghan Melberg AU - Yijia Li AU - Rebecca F. Gilbert AU - Zahra Reynolds AU - Surabhi L. Iyer AU - Grace C. Chamberlin AU - Tammy D. Vyas AU - Marcia B. Goldberg AU - Jatin M. Vyas AU - Jonathan Z. Li AU - Jacob E. Lemieux AU - Mark J. Siedner AU - Amy K. Barczak Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/03/02/2022.03.01.22271582.abstract N2 - Clinical features of SARS-CoV-2 Omicron variant infection, including incubation period and transmission rates, distinguish this variant from preceding variants. However, whether the duration of shedding of viable virus differs between omicron and previous variants is not well understood. To characterize how variant and vaccination status impact shedding of viable virus, we serially sampled symptomatic outpatients newly diagnosed with COVID-19. Anterior nasal swabs were tested for viral load, sequencing, and viral culture. Time to PCR conversion was similar between individuals infected with the Delta and the Omicron variant. Time to culture conversion was also similar, with a median time to culture conversion of 6 days (interquartile range 4-8 days) in both groups. There were also no differences in time to PCR or culture conversion by vaccination status.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Massachusetts Consortium for Pathogen Readiness (grants to J.Z.L, J.E.L, M.B.G., M.J.S, and A.K.B.) and the Massachusetts General Hospital Department of Medicine (grant to J.M.V.). The BSL3 laboratory where viral culture work was performed is supported by the Harvard CFAR (P30 AI060354).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Mass General Brigham IRB gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript. ER -